GlassScriptPhysician profile
Louisa Jones
NPI 1568997344
$5,478.36
in general payments reported to CMS, 2019-2025
33 companies · $2,866 in 2025
The $2,866 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.52 · 2022: $20.31 · 2023: $225 · 2024: $2,280 · 2025: $2,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,176 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,175.89 |
| Education | $194.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,138.61 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,071.95 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $498.41 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $382.81 | 2023-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $360.91 | 2024-2025 | |
| Mylan Specialty L.P. | $263.03 | 2023-2024 | Yupelri |
| Viatris Specialty LLC | $250.74 | 2025 | Yupelri |
| Verona Pharma, INC. | $233.97 | 2025 | Ohtuvayre |
| Insmed, INC. | $232.84 | 2024-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $182.99 | 2024-2025 | Opsumit, Uptravi |
| Electromed, INC. | $133.44 | 2024-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $82.90 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $71.86 | 2025 | Lumryz |
| Harmony Biosciences LLC | $65.93 | 2024-2025 | |
| Nevro Corp. | $48.74 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.54 | 2023-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $35.95 | 2025 | |
| Pulmonx Corporation | $35.06 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2025 | |
| La Jolla Pharmaceutical Company | $26.80 | 2025 | Giapreza |
| Zoll Respicardia, INC. | $25.69 | 2024 | Remede System |
| Inspire Medical Systems, INC. | $25.46 | 2025 | Inspire |
| Amgen INC. | $24.88 | 2025 | Tezspire |
| 3b Medical, INC. | $24.62 | 2025 | Luna |
| Idorsia Pharmaceuticals US INC | $22.98 | 2025 | Quviviq |
| Novo Nordisk INC | $21.66 | 2024 | Ozempic, Rybelsus |
| United Therapeutics Corporation | $20.69 | 2025 | Tyvaso |
| Lilly USA, LLC | $19.56 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2025 | Glassia |
| Breas Medical, INC. | $16.09 | 2025 | Vivo 45 Ls |
| Inogen, INC. | $15.90 | 2025 | |
| Almatica Pharma LLC | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louisa Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.